MARMC FAX

Mineral Area Regional Medical Center
1212 Weber Road
Farmington, Missouri 63640
FAX: (573)-701-7247

DATE/TIME: _____ **TO:** _____

FROM: _____ **PHONE#:** _____

DEPARTMENT: Medical Imaging **FAX#:** 573-701-7247

PHONE#: 573-701-7212 or 573-701-7450 **# PAGES SENT:** _____

Message:

Fax Cover
And
7 pages

Information Sent: _____

CONFIDENTIAL

Rev 8/14/2002

Mineral Area
REGIONAL MEDICAL CENTER

December 31, 2009

Materials Licensing Section
U.S. Nuclear Regulatory Commission, Region III
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532-4352

Licensing Agent:

Enclosed is a copy of a radioactive materials license, 24-00128-03 naming the following as an authorized users.

Rajinder M Gulati M.D.
Mark L Gates M.D.
George A Pjura M.D.

Mineral Area Regional Medical Center's administration and radiation safety committee has given them approval to be an authorized user at this facility under our license number 24-18040-01.

Please expedite this request by February 1st, 2010, if possible, so as not to interrupt patient services.

I would appreciate a return phone call to 573-701-7185 when this is received and in the processing stage.

Sincerely,

R.A. Murphy D.O.
Radiation Safety Officer
Mineral Area regional Medical Center

Bryan Hargis
Chief Executive Officer
Mineral Area Regional Medical Center

Official Use Only – Security-Related Information

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-00128-03
Docket or Reference Number
030-02264
Amendment No. 81

A. Individuals permitted to work as an authorized user and authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Craig W. Williams, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding Iodine-131 for thyroid carcinoma) and 35.500.
Willeford J. Stoecker, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 for thyroid carcinoma).
Mark L. Pfautsch, D.O.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Bryan S. Beck, M.D.	10 CFR 35.200.
Joseph Paul Miller, M.D.	10 CFR 35.300, 35.400, iridium-192 in HDR remote afterloading brachytherapy device and Iodine-125 in the Cytyc Surgical Products II GliaSite® Radiotherapy System
Kenneth Retter, M.D.	10 CFR 35.200 and 35.500
Rajinder M. Gulati, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Mark L. Gates, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
George A. Pjura, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Tom B. Brumitt, D.O.	10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 for thyroid carcinoma).
Theodore R. Swartz, M.D.	10 CFR 35.100, 35.200 and 35.500
Patricia O. MacFarlane, M.D.	10 CFR 35.100, 35.200 and 35.500
Andrew E. West, M.D.	10 CFR 35.100, 35.200 and 35.500
Christopher T. Russell, M.D.	10 CFR 35.100, 35.200 and 35.500
David A. Law, M.D.	10 CFR 35.200.
Huan Luong Nguyen, M.D.	10 CFR 35.100, 35.200 and 35.500.
James J. Borders, M.D.	10 CFR 35.100, 35.200 and 35.500.
Cedric C. Strange, M.D.	10 CFR 35.100, 35.200 and 35.500.
Jaganmohan Allinani, M.D.	10 CFR 35.100, 35.200 and 35.500.
Tom E. Moore, M.D.	10 CFR 35.100 and 35.200.

Official Use Only – Security-Related Information

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 4 of 6 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-00128-03
Docket or Reference Number
030-02264
Amendment No. 81

Authorized Users	Material and Use
Paul H. Holcomb, M.D.	10 CFR 35.100 and 35.200.
William Johnson, M.D.	10 CFR 35.600 limited to iridium-192 in HDR remote afterloading brachytherapy device.
Leeman P. Maxwell, M.D.	**10 CFR 35.200.**
Billy A.F. Hammond, M.D.	**10 CFR 35.200.**

C. The following individuals are Authorized Medical Physicist:

Authorized Users	Material and Use
Samuel S. Hancock, Ph.D.	Iridium-192 in High Dose Rate Remote Afterloading Brachytherapy device; strontium 90 ophthalmic applicator decay corrections; and for calibrations, spot checks and training.
Nicholas D. Schupp, M.S.	Iridium-192 in High Dose Rate Remote Afterloading Brachytherapy device; strontium 90 ophthalmic applicator decay corrections; and for calibrations, spot checks and training.

13. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

C. Sealed sources need not be leak tested if are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

Official Use Only – Security-Related Information

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-00128-03
Docket or Reference Number
030-02264
Amendment No. 81

D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

E. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

14. Sealed sources shall not be opened or removed from their respective source holders.

15. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by NRC, to account for all sources and/or devices received and possessed under the license.

16. When using technetium-99m aerosol, the license shall collect spent aerosol in a shielded trap and, for reusable traps, the licensee shall monitor the trap effluent with an air contamination monitor. The air contamination monitor shall be checked in accordance with the manufacturer's instructions. Effluent from single use traps are not required to be monitored.

17. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

18. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

Official Use Only – Security-Related Information

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-00128-03
Docket or Reference Number
030-02264
Amendment No. 81

19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 23, 2000;

B. Letters dated August 5, 2003, September 5, 2003, December 20, 2005, June 30, 2006, July 7, 2006, June 11, 2008, August 22, 2008; and,

C. Facsimiles dated September 23, 2003, August 18, 2006, September 20, 2006, September 27, 2006, October 2, 2006, October 5, 2006, October 19, 2006 and October 23, 2006.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAY 0 5 2009

By Colleen Carol Casey

Colleen Carol Casey
Materials Licensing Branch
Region III

Official Use Only – Security-Related Information

Official Use Only – Security-Related Information

NRC FORM 374 PAGE 1 OF 8 PAGES

U.S. NUCLEAR REGULATORY COMMISSION Amendment No. 81

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letters dated January 30, 2008, (received February 5, 2009), April 10, 2009, and April 23, 2009,
1. Southeast Missouri Hospital	3. License number 24-00128-03 is amended in its entirety to read as follows:
2. 1701 Lacey Street Cape Girardeau, MO 63701	4. Expiration date November 30, 2010
	5. Docket No. 030-02264 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of Iodine-131)
D. Any byproduct material permitted by 10 CFR 35.400	D. As listed in Subitem 9.D.	D. 1 curie
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed sources (Isotope Products Laboratories HEG-137, North American Scientific MED3601)	E. 1 curie
F. Iridium-192, as permitted by 10 CFR 35.600	F. Varian Medical Systems GammaMed 232	F. Two sources not to exceed 20 curies total
G. Iodine-125, as permitted by 10 CFR 35.1000	G. Liquid as Iotrex™	G. 4 curies

Official Use Only – Security-Related Information

Official Use Only – Security-Related Information

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 of 6 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-00128-03
Docket or Reference Number
030-02264
Amendment No. 81

H. Depleted Uranium	H. Stainless steel covered metal	H. 4 shields, not to exceed 12 kilograms each

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400. Sealed sources authorized include AEA Technology Model Nos. 6501, 6502, 6503, 6504, 6523 and 6524; Bard STM 1251; Amersham OncoSeed 6711; Medi-Physics, Inc. EchoSeed 6733; Best Medical International, Inc. 2301; Mills Biopharmaceuticals, LLC, I125SL; North American Scientific MED 3631; Theragenics Corp. I125.S06; IsoAid, LLC, I-125 IAI-125A Advantage; International Brachytherapy, Inc. InterSource Model 1251L; Implant Sciences Corp. I-Plant 3500; Nucletron Corporation SelectSeed I-125; Best Medical International, Inc. 2335; International Brachytherapy, Inc. OptiSeed-103 1032p; North American Scientific MED 3633; Theragenics TheraSeed 200; IsoAid Advantage IAPD-103A; Mills Biopharmaceuticals, LLC, Pd2335; IsoRay CS-1; and DuPont Merck Pharmaceutical Co. Model NB-1.

E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

F. One source for medical use, as permitted by 10 CFR 35.600, in a Varian Medical Systems High Dose Rate remote afterloading brachytherapy device. The source activity may not exceed 10 curies at the time of medical use. One source in its shipping container for source replacement.

G. For use in the Cytyc Surgical Products II GliaSite® Radiotherapy System for medical use permitted by 10 CFR 35.1000.

H. Shielding in ADAC Laboratories MCD-AC attenuation correction system.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1701 Lacey Street, Cape Girardeau, Missouri

11. Radiation Safety Officer: Samuel S. Hancock, Ph.D.

12. Licensed material is only authorized for use by, or under the supervision of: